Pre-made Tarextumab benchmark antibody ( Whole mAb, anti-NOTCH2&3 therapeutic antibody, Anti-AGS2/HJCYS/hN2;CADASIL/CADASIL1/CASIL/IMF2/LMNS Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-551

Pre-Made Tarextumab biosimilar, Whole mAb, Anti-NOTCH2&3 Antibody: Anti-AGS2/HJCYS/hN2;CADASIL/CADASIL1/CASIL/IMF2/LMNS therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tarextumab (formerly OMP-59R5) is a fully human monoclonal antibody targeting the Notch 2/3 receptors. It is being tested as a possible treatment for cancer. In January 2015, the US FDA granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and lung cancer. Two early stage clinical trials have reported encouraging results.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-551-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Tarextumab biosimilar, Whole mAb, Anti-NOTCH2&3 Antibody: Anti-AGS2/HJCYS/hN2;CADASIL/CADASIL1/CASIL/IMF2/LMNS therapeutic antibody
INN Name Tarextumab
TargetNOTCH2&3
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2013
Year Recommended2014
CompaniesOncoMed Pharmaceuticals
Conditions Approvedna
Conditions ActivePancreatic cancer;Small cell lung cancer
Conditions DiscontinuedSolid tumours
Development TechMorphoSys HuCAL Phage Display;XmAb Engineering Technology